Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 7 for:    PolyPid

D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II) (D-PLEX 312)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04411199
Recruitment Status : Not yet recruiting
First Posted : June 2, 2020
Last Update Posted : September 9, 2020
Sponsor:
Information provided by (Responsible Party):
PolyPid Ltd.

Brief Summary:
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surgery Incisional Infection.

Condition or disease Intervention/treatment Phase
Surgical Site Infection Colon Surgery Abdominal Surgery Post-Op Infection Drug: D-PLEX Other: Standard of Care (SoC) Phase 3

Detailed Description:

D-PLEX is a new formulation of extended controlled release of Doxycycline in the applied area for about 30 days. This study is aimed to assess the safety and efficacy of D-PLEX in prevention of post abdominal surgery incisional infection.

The study population includes male and female, 18 years old and above at screening, undergoing an elective colorectal surgery involving colon or rectal resection, with or without a stoma formation, that includes at least 1 incision that is ≥ 7cm (target incision).

Eligible and willing subjects will be randomly allocated into 2 blinded study arms, either to the investigational arm (D-PLEX + SoC) or to the control arm (SoC only) in a 1:1 ratio. Subjects will be stratified by incisional length (7cm ≤10 cm, >10 ≤20cm, >20cm), type of prophylactic SoC (IV antibiotic only, IV antibiotic with mechanical bowel preparation or IV antibiotic with oral antibiotics combined with mechanical bowel preparation) and by region (US versus Europe + Israel).

D-PLEX will be applied during the surgery at the final stage of incision closure. All patients will be followed up for additional 5 visits over 2 months, for safety and incisional wound assessment. This will include blood tests for hematology and chemistry as well as physician's assessment of the incisional wound.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Males and females, >18 years old, undergoing scheduled abdominal colon surgery involving resection and anastomosis or a stoma, who meet the inclusion criteria and none of the exclusion criteria and provide signed informed consent will be enrolled in the study.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:

This is a double-blind clinical trial. The sponsor, the subjects, outcomes assessor and all staff involved in the collection and recording of the clinical and laboratory data, based on which the independent adjudication committee will perform their assessment, will be blind to treatment assignment. In addition, all aspects of data management and clean-up will be done in blinded datasets.

The study site personnel, who perform the index surgery (Operation room staff), will be trained not to disclose the treatment arm to the blinded Investigator, to the subject, his/her family, to other health care providers not present during the surgery or to the study Sponsor representatives. Wound assessment throughout the study follow-up visits will be done by a blinded Investigator, that will not be involved in the surgery. An emergency card containing the Study Name, NIH number, Center Name/number, PI's name and contact details will be provided to the subjects.

Primary Purpose: Prevention
Official Title: D-PLEX 312 - Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX In Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : September 2022

Arm Intervention/treatment
Experimental: D-PLEX+SoC
D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
Drug: D-PLEX
D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.

Other: Standard of Care (SoC)
prophylactic, pre-operation per institution guidelines

Standard of Care
The SoC for prophylactic antibiotic treatment is based on international guidelines
Other: Standard of Care (SoC)
prophylactic, pre-operation per institution guidelines




Primary Outcome Measures :
  1. To assess the anti-infective efficacy of D-PLEX over a period of 30 days post operation, by preventing surgical site infection (SSI), defined as superficial and deep infection, in the target incision(s), compared to the SoC treated control. [ Time Frame: By day 30 post surgery ]

    Infection rate as measured by the proportion of subjects with at least one abdominal incisional infection event, as determined by a blinded and independent adjudication committee, within 30 days post abdominal surgery. [abdominal incisional infection is composed of Deep Incisional Surgical Site Infection (DSSI) and Superficial Incisional Surgical Site Infection (SSSI)].within 30 days post abdominal surgery and determined by a blinded and independent adjudication committee.

    All-cause mortality and re-interventions in the target incision within 30 days post index surgery will be analysed as treatment failure.

    Incisional infection event only, occurred within 30 days post abdominal surgery and determined by a blinded and independent adjudication committee.

    [abdominal incisional infection is defined as Deep Incisional Surgical Site Infection (DSSI) and/or Superficial Incisional Surgical Site Infection (SSSI)].


  2. Safety of D-PLEX in Prevention of Post Abdominal Surgery [ Time Frame: By day 60 post surgery ]
    Safety parameters will be evaluated by adverse events

  3. Safety of D-PLEX in Prevention of Post Abdominal Surgery Incisional [ Time Frame: By day 60 post surgery ]
    Incisional wound healing will be assessed by a blinded Investigator, using a visual examination as well as Modified Vancouver Scar Scale wound assessment questionnaires. The questionnaire has a numeric scale from 0-4 in Vascularity, Pigmentation, Pliability and height


Secondary Outcome Measures :
  1. Assessment of Infection rate in patient undergoing abdominal colon surgery [ Time Frame: At study visits: day 1, day 5, day 14 and day 30 post surgery ]

    Infection rate as measured by the proportion of subjects with at least one abdominal incisional infection event only, occurred within 30 days post abdominal surgery and determined by a blinded and independent adjudication committee.

    [abdominal incisional infection is defined as Deep Incisional Surgical Site Infection (DSSI) and/or Superficial Incisional Surgical Site Infection (SSSI)].




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects undergoing a colorectal surgery involving resection, with or without a stoma formation, that includes at least 1 incision that is ≥ 7cm (target incision).
  2. Subjects are preoperative hemodynamically stable.
  3. Male or non-pregnant female.
  4. Female of child-bearing potential should have a negative pregnancy test (serum or urine dipstick) prior to index procedure. Note: All female subjects of child-bearing potential must agree to use a highly effective method of contraception consistently and correctly for the duration of the study.
  5. Subjects age 18 years old and above at screening.
  6. Subjects who sign a written Informed Consent Form.
  7. Subjects who are willing and able to participate and meet all study requirements.
  8. Survival expectancy of at least 60 days post randomization.

Exclusion Criteria:

  1. Subjects with any preoperative infection or who are receiving any antibiotic therapy in the past 1 week prior to randomization, besides prophylaxis or antibiotic for the treatment of the disease that consists the indication for surgery.
  2. Subjects undergoing concomitant additional major procedures besides abdominal surgery. Female sterilization surgery (i.e. salpingo-oophorectomy etc.), involvement of a small bowel procedure or cholecystectomy may be allowed, pending an advanced consultation and approval from the Sponsor.
  3. Subject received anti-cancer treatment within the last 4 weeks of surgery, or radiation for colorectal cancer to the abdomen area, prior to the planned abdominal surgery.
  4. Subjects that received oral or IV Doxycycline/Tetracycline family antibiotic during the past 4 weeks prior to randomization.
  5. Subjects with known allergy to Doxycycline and/or to the tetracycline family of drugs or to the D-PLEX's excipients.
  6. Subjects with known allergies to more than 3 substances (an allergy questionnaire will be filled in during the screening process).
  7. Subjects with history of severe allergic reaction to any substance, having required treatment with intravenous steroids/intramuscular epinephrine, or in the opinion of the Investigator the subject is at high risk of developing severe allergic reactions.
  8. Subjects with End Stage Renal Disease (ESRD/CKD stage 5).
  9. Subjects with chronic urticaria.
  10. Subjects diagnosed with TIA/CVA within the past 6 months prior to randomization.
  11. Subjects that undergone any abdominal surgery and current planned surgery involves re-opening the scar of a prior abdominal surgery performed within the last 5 years.
  12. Any subject with active malignancy or with malignancy that has not been in complete remission for at least 3 years. Excluding:

    • Subjects with potentially resectable non-metastatic cancer which consists of the indication for the surgery.
    • Subjects who have had carcinoma in situ (or other cancer "in situ = Stage 0"), squamous cell carcinoma of the skin and basal cell carcinoma of the skin.
    • Subjects with any additional non-violent cancer (slowly growing, localized or chronic cancers), that does not require treatment 4 weeks prior to the surgery, and throughout the entire study duration.
  13. Subjects with other concurrent severe and/or uncontrolled medical condition that could compromise participation in the study.
  14. Psychiatric or any other disorder that compromises ability to provide Informed Consent Form for participation in this study.
  15. Chronic alcoholic or drug abuse subjects.
  16. Pregnant or breast-feeding women or women of child-bearing age who refuse or prohibited of using an effective contraceptive method of birth control throughout study participation, including safety follow-up period.
  17. Subjects that received any investigational drug within 30 days or 5 half-lives of randomization to the study (whichever is longer).
  18. Subjects participating in any other interventional studies.
  19. In the opinion of Investigator, subject is not eligible to participate in the study and/or to comply with protocol requirements (e.g. due to a cognitive or medical condition).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04411199


Contacts
Layout table for location contacts
Contact: Ilana Sufaro, CPM +972 74-7195700 ilana.s@polypid.com
Contact: Iris Gelber, COM +972 74-7195700 iris.g@polypid.com

Sponsors and Collaborators
PolyPid Ltd.
Layout table for additonal information
Responsible Party: PolyPid Ltd.
ClinicalTrials.gov Identifier: NCT04411199    
Other Study ID Numbers: D-PLEX 312
First Posted: June 2, 2020    Key Record Dates
Last Update Posted: September 9, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by PolyPid Ltd.:
Surgical site infection
Abdominal surgery
Colon and small bowl surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Surgical Wound Infection
Wound Infection
Postoperative Complications
Pathologic Processes